1. The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer.
- Author
-
Ducceschi, Monika, Polignano, Maggie, Bini, Marta, Lopez, Salvatore, Conca, Elena, Tamborini, Elena, Perrone, Federica, Carlo Stella, Giulia, Petrella, Maria Cristina, Carciotto, Rosaria, Artioli, Grazia, Maffeis, Valeria, Sartor, Lucia, Raspagliesi, Francesco, and Mantiero, Mara
- Subjects
- *
ENDOMETRIAL cancer , *IMMUNE checkpoint inhibitors , *GYNECOLOGIC cancer , *IMMUNE checkpoint proteins , *IMMUNOTHERAPY , *MONOCLONAL antibodies - Abstract
Patients with solid tumors and mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are eligible for immunotherapy. Recently, different reports described patients with poor performance status (PS), unrelated to comorbidities, which showed a rapid improvement of their clinical conditions under immunotherapy, which evoked a Lazarus response. Very few data on the efficacy and safety of immunotherapy in patients with gynecological malignancies and poor PS are available. Based on the GARNET trial, Dostarlimab, a monoclonal antibody anti-programmed death receptor-1 (PD-1), has been approved in advanced or recurrent mismatch repair deficient endometrial cancer (EC) which progressed after platinum-based therapy. For the first time, in gynecological oncology, an immune checkpoint inhibitor drastically changed the clinical practice. We collected a multicenter case series of six patients with advanced endometrial carcinoma and PS ECOG 3–4 treated with Dostarlimab, showing exceptionally quick responses and significant improvement of PS to configure a Lazarus response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF